Vertex Exceeds Profit Estimates with Strong Cystic Fibrosis Drug Sales Surge

• Alyftrek, a once-daily triple combination CF therapy, saw sales jump nearly eight-fold to $424.4 million in Q1, up from $53.9 million in the prior year period
• Trikafta, Vertex's older CF drug, brought in $2.35 billion but missed analyst estimates of $2.64 billion for the quarter
• Journavx, the company's non-opioid pain treatment, generated $29 million in revenue with over 350,000 prescriptions filled in Q1 2026 and more than 1 million total since its March 2025 launch

Vertex Pharmaceuticals Beats Q1 Profit Estimates on Cystic Fibrosis Drug Momentum

Vertex Pharmaceuticals exceeded Wall Street's first-quarter adjusted profit expectations on May 4, reporting earnings of $4.47 per share, driven by exceptional performance from its cystic fibrosis (CF) drug portfolio.

Key Financial Performance:

• Quarterly revenue rose 8% to $2.99 billion, slightly below analyst estimates of $3.02 billion
• Full-year revenue guidance maintained at $12.95 billion to $13.1 billion

Drug Performance Highlights:

Alyftrek, Vertex's once-daily triple combination CF therapy, delivered breakthrough results with sales of $424.4 million in Q1, up 687% from $53.9 million in the prior-year period. However, the company's established CF drug Trikafta generated $2.35 billion in sales, missing analyst expectations of $2.64 billion.

Diversification Strategy:

As a dominant player in cystic fibrosis treatment, Vertex is actively pursuing growth beyond CF through:

• Casgevy: Gene therapy targeting sickle cell disease and transfusion-dependent beta-thalassemia
• Journavx: Non-opioid pain treatment showing strong market uptake with over 1 million prescriptions filled since its March 2025 launch, including 350,000 prescriptions in Q1 2026 alone, generating $29 million in revenue

Market Implications:

The results demonstrate Vertex's successful product transition within its core CF franchise while establishing early traction in new therapeutic areas. The mixed revenue performance—with newer CF treatments surging but Trikafta underperforming—suggests ongoing portfolio evolution. The company's diversification into gene therapy and pain management positions it for sustained growth beyond its CF stronghold.